A Phase 1 Open-Label, Dose Escalation Study of OTX-TKI for Intravitreal Use in Subjects With Neovascular Age-Related Macular Degeneration (AMD)
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Aug 2018
At a glance
- Drugs OTX-TKI (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors Ocular Therapeutix
- 09 Aug 2018 Status changed from planning to not yet recruiting.
- 27 Apr 2018 According to an Ocular Therapeutix media release, company plans to initiate this trial in the second quarter of 2018.
- 07 Nov 2017 According to an Ocular Therapeutix media release, Company expects to initiate this trial outside the United States for OTX-TKI in the first half of 2018.